Importance of IgG2c isotype in the immune response to β-amyloid in amyloid precursor protein/transgenic mice

Neuroscience Letters

Volumn 338, Issue 1, 2003, Pages 5-8

  Petrushina, Irina ^a   Tran, Mike ^a   Sadzikava, Nadya ^b   Ghochikyan, Anahit ^b   Vasilevko, Vitaly ^b   Agadjanyan, Michael G ^b   Cribbs, David H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUTE FOR MOLECULAR MEDICINE   (United States)

Author keywords

Amyloid precursor protein transgenic mice; A 42; Ig isotypes; IgG2a and IgG2c genes

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA AMYLOID ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G2A; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; HISTOCOMPATIBILITY COMPLEX; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOASSAY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; TRANSGENIC MOUSE;

EID: 0037455923     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(02)01357-5     Document Type: Article

References (17)

1. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:2000;916-919.
2. Borchelt D.R., Ratovitski T., van Lare J., Lee M.K., Gonzales V., Jenkins N.A., Copeland N.G., Price D.L., Sisodia S.S. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 19:1997;939-945.
3. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 98:2001;8850-8855.
4. Dickey C.A., Morgan D.G., Kudchodkar S., Weiner D.B., Bai Y., Cao C., Gordon M.N., Ugen K.E. Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide. DNA Cell Biol. 2001;723-729.
5. Finkelman F.D., Holmes J., Katona I.M., Urban J.F., Beckmann M.P., Park L.S., Schooley K.A., Coffman R.L., Mossmann T.R., Paul W.E. Lymphokine control of in vivo immunoglobulin isotype selection. Ann. Rev. Immunol. 8:1990;303-333.
6. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., Guido T., Hagopian S., Johnson K., Khan K., Lee M., Leibowitz P., Lieberburg I., Little S., Masliah E., McConiogue L., Montoya-Zavala M., Mucke L., Paganini L., Penniman E., Power M., Schenk D., Seubert P., Snyder B., Soriano F., Tan H., Vitalo J., Wadsworth S., Wolozin B., Zhao J. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 373:1995;523-527.
7. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits: Abeta elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102.
8. Janus C., Chishti M.A., Westaway D. Transgenic mouse models of Alzheimer's disease. Biochim. Biophys. Acta. 1502:2000;63-75.
9. Jouvin-Marche E., Morgado M.G., Leguern C., Voegtle D., Bonhomme F., Cazenave P.A. The mouse Igh-1a and Igh-1b H chain constant regions are derived from two distinct isotypic genes. Immunogenetics. 29:1989;92-97.
10. Lemere C.A., Maron R., Selkoe D.J., Weiner H.L. Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol. 20:2001;705-711.
11. Martin R.M., Brady J.L., Lew A.M. The need for IgG2c specific antiserum when isotyping antibodies from C57Bl/6 and NOD mice. J. Immunol. Methods. 212:1998;187-192.
12. Monsonego A., Maron R., Zota V., Selkoe D.J., Weiner H.L. Immune hyporesponsiveness to amyloid b-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 98:2001;10273-10278.
13. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:2000;982-985.
14. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
15. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA. 94:1997;13287-13292.
16. Town T., Tan J., Sansone N., Obregon D., Klein T., Mullan M. Characterization of murine immunoglobulin G antibodies against human amyloid-b 1-42. Neurosci. Lett. 307:2001;101-104.
17. Vehmas A.K., Borchelt D.R., Price D.L., McCarthy D., Wills-Karp M., Peper M.J., Rudow G., Luyinbazi J., Siew L.T., Troncoso J.C. Beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip technology. DNA Cell Biol. 20:2001;713-721.